RedHill Biopharma hält Präsentation auf Deutschem Eigenkapitalforum 2020
16. November 2020 09:27 ET
|
RedHill Biopharma Ltd.
TEL-AVIV, Israel und RALEIGH, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen,...
RedHill Biopharma to Present at German Equity Forum 2020
13. November 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth
12. November 2020 07:00 ET
|
RedHill Biopharma Ltd.
Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020--Strong growth for Talicia® with...
RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 2020
05. November 2020 07:00 ET
|
RedHill Biopharma Ltd.
TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that...
RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination
04. November 2020 10:30 ET
|
RedHill Biopharma Ltd.
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP...
RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication
26. Oktober 2020 09:00 ET
|
RedHill Biopharma Ltd.
H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining...
RedHill Biopharma объявляет партнеров для расширения производства Opaganib как потенциального средства терапии для лечения COVID-19
15. Oktober 2020 01:46 ET
|
RedHill Biopharma Ltd.
Сотрудничество с европейскими и канадскими поставщиками для крупномасштабного наращивания производства opaganib еще больше укрепляет производственные возможности и мощности в рамках подготовки к...
RedHill Biopharma annonce des partenariats visant à augmenter la fabrication de l'opaganib, candidat thérapeutique pour le traitement du COVID-19
15. Oktober 2020 01:00 ET
|
RedHill Biopharma Ltd.
Les collaborations avec des fournisseurs européens et canadiens pour une montée en puissance à grande échelle de la fabrication de l'opaganib renforcent davantage les capacités de fabrication, en...
RedHill Biopharma宣布合作伙伴关系以扩大新冠肺炎候选药物opaganib的制造规模
14. Oktober 2020 19:00 ET
|
RedHill Biopharma Ltd.
与欧洲和加拿大供应商就opaganib的大规模增产进行合作进一步加强制造能力和产能，为潜在的紧急用药申请获批做好准备--使用opaganib治疗新冠肺炎全球2/3期研究的患者招募在6个国家予以批准后迅速推进--在美国进行的opaganib治疗新冠肺炎2期研究即将完成患者招募，并于最近通过了独立委员会第二次审查 以色列特拉维夫和北卡罗来纳罗利, Oct. 15, 2020 (GLOBE...
RedHill Biopharma 宣佈合作夥伴關係，以擴大 COVID-19 治療候選藥物 Opaganib 的生產
14. Oktober 2020 19:00 ET
|
RedHill Biopharma Ltd.
為準備申請緊急使用授權，RedHill Biopharma 與歐洲和加拿大供應商合作以擴大 opaganib 的生產規模，進一步提升製造能力和產能-- 在 6 個國家 / 地區獲批後，使用 opaganib 治療 COVID-19 的全球第 2/3 期研究納入工作正在快速進行--使用 opaganib 治療...